A preclinical and clinical rationale for quetiapine in mood syndromes

Bibliography

• KELLER MB: Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA (2003) 289(23):3152-3160.
   PubMed Web of Science ®Google Scholar
• TRIVEDI MH, RUSH AJ, WISNIEWSKI SR et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry (2006) 163(1):28-40.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JA: Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry (2006) 63(10):1069-1072.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, KONARSKI JZ: Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry (2004) 66 (Suppl. 3):28-36.
   Google Scholar
• LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353(12):1209-1223.
   PubMed Web of Science ®Google Scholar
• PERLIS RH, WELGE JA, VORNIK LA et al.: Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry (2006) 67(4):509-516.
   PubMed Web of Science ®Google Scholar
• SUPPES T, DENNEHY EB, HIRSCHFELD RM et al.: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry (2005) 66(7):870-886.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, KENNEDY SH, O'DONOVAN C et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. (2005) 7(Suppl. 3):5-69.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, LAM RW, COHEN NL et al.: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry (2001) 46(Suppl.1):38S-58S.
   PubMedGoogle Scholar
• BAUNE BT, CALISKAN S, TODDER D: Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum. Psychopharmacol. (2007) 22(1):1-9.
   PubMed Web of Science ®Google Scholar
• BERMAN RM, CHARNEY DS: Models of antidepressant action. J. Clin. Psychiatry (1999) 60(Suppl. 14):16-20.
   PubMedGoogle Scholar
• O'NEIL MF, MOORE NA: Animal models of depression: are there any? Hum. Psychopharmacol. (2003) 18(4):239-254.
   PubMed Web of Science ®Google Scholar
• BLIER P, SZABO ST: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry (2005) 66(Suppl. 8):30-40.
   PubMed Web of Science ®Google Scholar
• DELGADO PL: Depression: the case for a monoamine deficiency. J. Clin. Psychiatry (2000) 61(Suppl. 6):7-11.
   PubMed Web of Science ®Google Scholar
• TAYLOR C, FRICKER AD, DEVI LA et al.: Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal. (2005) 17(5):549-557.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, GOLDSTEIN JM, VIETA E et al.: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry (2005) 66(Suppl. 5):40-48.
   PubMed Web of Science ®Google Scholar
• HOU C, JIA F, LIU Y et al.: CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res. (2006) 1095(1):154-158.
   PubMed Web of Science ®Google Scholar
• MINTUN MA, SHELINE YI, MOERLEIN SM et al.: Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol. Psychiatry (2004) 55(3):217-224.
   PubMed Web of Science ®Google Scholar
• BAKISH D, LAPIERRE YD, WEINSTEIN R et al.: Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J. Clin. Psychopharmacol. (1993) 13(6):409-414.
   PubMed Web of Science ®Google Scholar
• KAPUR S, SEEMAN P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry (2001) 158(3):360-369.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA J, LI Z, DAI J et al.: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. (2002) 956(2):349-357.
   PubMed Web of Science ®Google Scholar
• DAVIES MA, SETOLA V, STRACHAN RT et al.: Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. (2006) 6(1):42-51.
   PubMed Web of Science ®Google Scholar
• JENSEN J, MCINTOSH AR, CRAWLEY AP et al.: Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron (2003) 40(6):1251-1257.
   PubMed Web of Science ®Google Scholar
• TARAZI FI, ZHANG K, BALDESSARINI RJ: Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci. Lett. (2000) 287(2):81-84.
   PubMed Web of Science ®Google Scholar
• STAHL SM, ZHANG L, DAMATARCA C et al.: Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J. Clin. Psychiatry (2003) 64 (Suppl. 14):6-17.
   Google Scholar
• HOEBEL BG: Brain neurotransmitters in food and drug reward. Am. J. Clin. Nutr. (1985) 42(5 Suppl.):1133-1150.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc ) (1999) 35(3):193-210.
   PubMed Web of Science ®Google Scholar
• MEYER JH, MCNEELY HE, SAGRATI S et al.: Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am. J. Psychiatry (2006) 163(9):1594-602.
   PubMed Web of Science ®Google Scholar
• KALIVAS PW, VOLKOW ND: The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry (2005) 162(8):1403-1413.
   PubMed Web of Science ®Google Scholar
• DIEHL DJ, GERSHON S: The role of dopamine in mood disorders. Compr. Psychiatry (1992) 33(2):115-120.
   PubMed Web of Science ®Google Scholar
• NEUMEISTER A, WILLEIT M, PRASCHAK-RIEDER N et al.: Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol. Med. (2001) 31(8):1467-1473.
   PubMed Web of Science ®Google Scholar
• DI MASCIO M, DI GIOVANNI G, DI MATTEO V, PRISCO S, ESPOSITO E: Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res. Bull. (1998) 46(6):547-554.
   PubMed Web of Science ®Google Scholar
• LAMMERS CH, DIAZ J, SCHWARTZ JC et al.: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry (2000) 5(4):378-388.
   PubMed Web of Science ®Google Scholar
• ICHIKA WA J, ISHII H, BONACCORSO S et al.:5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. (2001) 76(5):1521-1531.
   PubMed Web of Science ®Google Scholar
• GEFVERT O, LUNDBERG T, WIESELGREN IM et al.: D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. (2001) 11(2):105-110.
   PubMed Web of Science ®Google Scholar
• LAMMERS CH, DIAZ J, SCHWARTZ JC et al.: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry (2000) 5(4):378-388.
   PubMed Web of Science ®Google Scholar
• SZEKERES G, KERI S, JUHASZ A et al.: Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2004) 124(1):1-5.
   Google Scholar
• BRUNELLO N, BLIER P, JUDD LL et al.: Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int. Clin. Psychopharmacol. (2003) 18(4):191-202.
   PubMed Web of Science ®Google Scholar
• WESTENBERG HG: Pharmacology of antidepressants: selectivity or multiplicity? J. Clin. Psychiatry (1999) 60 (Suppl. 17):4-8.
   PubMedGoogle Scholar
• PIRA L, MONGEAU R, PANI L: The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. (2004) 504(1-2):61-64.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JM, CRISTOPH G, GRIMM S et al.: Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine. American Psychiatric Association's 160th Annual Meeting. San Diego, California, USA (19 – 24 May 2007).
   Google Scholar
• KRYSTAL JH, SANACORA G, BLUMBERG H et al.: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry (2002) 7(Suppl. 1):S71-S80.
   PubMed Web of Science ®Google Scholar
• PAUL IA, SKOLNICK P: Glutamate and depression: clinical and preclinical studies. Ann. N Y Acad. Sci. (2003) 1003:250-272.
   PubMed Web of Science ®Google Scholar
• GERBER U, GEE CE, BENQUET P: Metabotropic glutamate receptors: intracellular signaling pathways. Curr. Opin. Pharmacol. (2007) 7(1):56-61.
   PubMed Web of Science ®Google Scholar
• PALUCHA A, PILC A: On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pol. J. Pharmacol. (2002) 54(6):581-586.
   PubMedGoogle Scholar
• ZARATE CA, Jr, SINGH JB, CARLSON PJ et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry (2006) 63(8):856-864.
   PubMed Web of Science ®Google Scholar
• TASCEDDA F, LOVATI E, BLOM JM et al.: Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology (1999) 21(2):211-217.
   PubMed Web of Science ®Google Scholar
• MOMBEREAU C, KAUPMANN K, FROESTL W et al.: Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology (2004) 29(6):1050-1062.
   PubMed Web of Science ®Google Scholar
• FATEMI SH, STARY JM, EARLE JA et al.: GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. (2005) 72(2-3):109-122.
   Google Scholar
• FATEMI SH, STARY JM, EARLE JA et al.: GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. (2005) 72(2-3):109-122.
   Google Scholar
• YAN Z: Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol. Neurobiol. (2002) 26(2-3):203-216.
   PubMed Web of Science ®Google Scholar
• ZINK M, SCHMITT A, MAY B et al.: Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr. Res. (2004) 66(2-3):151-157.
   Google Scholar
• YOKOTA K, TATEBAYASHI H, MATSUO T et al.: The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics. Br. J. Pharmacol. (2002) 135(6):1547-1555.
   PubMed Web of Science ®Google Scholar
• MARX CE, VANDOREN MJ, DUNCAN GE et al.: Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology (2003) 28(1):1-13.
   PubMed Web of Science ®Google Scholar
• POPOLI M, BRUNELLO N, PEREZ J et al.: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J. Neurochem. (2000) 74(1):21-33.
   PubMed Web of Science ®Google Scholar
• POPOLI M, BRUNELLO N, PEREZ J et al.: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J. Neurochem. (2000) 74(1):21-33.
   PubMed Web of Science ®Google Scholar
• DUMAN RS: Pathophysiology of depression: the concept of synaptic plasticity. Eur. Psychiatry (2002) 17(Suppl. 3):306-310.
   Google Scholar
• FUMAGALLI F, MOLTENI R, BEDOGNI F et al.: Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport (2004) 15(13):2109-2112.
   PubMed Web of Science ®Google Scholar
• POPOLI M, BRUNELLO N, PEREZ J et al.: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J. Neurochem. (2000) 74(1):21-33.
   PubMed Web of Science ®Google Scholar
• MCEWEN BS: Stress and hippocampal plasticity. Annu. Rev. Neurosci. (1999) 22:105-122.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO K, SHIMIZU E, IYO M: Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. (2004) 45(2):104-114.
   Web of Science ®Google Scholar
• GONUL AS, AKDENIZ F, TANELI F et al.: Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. (2005) 255(6):381-386.
   PubMed Web of Science ®Google Scholar
• XU H, QING H, LU W et al.: Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. (2002) 321(1-2):65-68.
   PubMed Web of Science ®Google Scholar
• PARK SW, LEE SK, KIM JM et al.: Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci. Lett. (2006) 402(1-2):25-29.
   PubMed Web of Science ®Google Scholar
• LUO C, XU H, LI XM: Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. (2005) 1063(1):32-39.
   PubMed Web of Science ®Google Scholar
• LICINIO J, WONG ML: The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry (1999) 4(4):317-327.
   PubMed Web of Science ®Google Scholar
• SCHIEPERS OJ, WICHERS MC, MAES M: Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(2):201-217.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, BETAN E, LARSEN H et al.: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol. Psychiatry (2003) 54(3):317-329.
   PubMed Web of Science ®Google Scholar
• CAPURON L, MILLER AH: Cytokines and psychopathology: lessons from interferon-α. Biol. Psychiatry (2004) 56(11):819-824.
   PubMed Web of Science ®Google Scholar
• CAPURON L, GUMNICK JF, MUSSELMAN DL et al.: Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 26(5):643-652.
   PubMed Web of Science ®Google Scholar
• KENIS G, MAES M: Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. (2002) 5(4):401-412.
   PubMed Web of Science ®Google Scholar
• KHANZODE SD, DAKHALE GN, KHANZODE SS et al.: Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. (2003) 8(6):365-370.
   PubMed Web of Science ®Google Scholar
• ALTSCHULER EL, KAST RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med. Hypotheses (2005) 65(1):65-67.
   PubMed Web of Science ®Google Scholar
• RUSH AJ, GILES DE, SCHLESSER MA et al.: The dexamethasone suppression test in patients with mood disorders. J. Clin. Psychiatry (1996) 57(10):470-484.
   PubMed Web of Science ®Google Scholar
• TARAZI FI, ZHANG K, BALDESSARINI RJ: Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide (2002) 7(4):297-300.
   PubMed Web of Science ®Google Scholar
• CORYELL W, YOUNG E, CARROLL B: Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortality in major depressive disorder. Psychiatry Res. (2006) 142(1):99-104.
   PubMed Web of Science ®Google Scholar
• PLOTSKY PM, OWENS MJ, NEMEROFF CB: Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr. Clin. North Am. (1998) 21(2):293-307.
   PubMed Web of Science ®Google Scholar
• BELANOFF JK, ROTHSCHILD AJ, CASSIDY F et al.: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry (2002) 52(5):386-392.
   PubMed Web of Science ®Google Scholar
• YOUNG AH, GALLAGHER P, WATSON S et al.: Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology (2004) 29(8):1538-1545.
   PubMed Web of Science ®Google Scholar
• COHRS S, ROHER C, JORDAN W et al.: The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) (2006) 185(1):11-18.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, KECK PE, JR, MACFADDEN W et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry (2005) 162(7):1351-1360.
   PubMed Web of Science ®Google Scholar
• THASE ME, MACFADDEN W, WEISLER RH et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J. Clin. Psychopharmacol. (2006) 26(6):600-609.
   PubMed Web of Science ®Google Scholar
• ZARATE CA, Jr:, TOHEN M: Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am. J. Psychiatry (2004) 161(1):169-171.
   PubMed Web of Science ®Google Scholar
• TOHEN M, VIETA E, CALABRESE J et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60(11):1079-1088.
   PubMed Web of Science ®Google Scholar
• CORYA SA, ANDERSEN SW, DETKE HC et al.: Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry (2003) 64(11):1349-1356.
   PubMed Web of Science ®Google Scholar